Supreme(R) Drug Eluting Stent performs equivalent to best-in-class in the PIONEER III publication
PR92500
TIANJIN, China, Oct. 27, 2021 /PRNewswire=KYODO JBN/ --
SINOMED, a leading international medical device company, announced that the
clinical trial results for its HT Supreme(R) Drug-Eluting Stent (DES) System
has been published in Circulation. The article described results from the
PIONEER III trial where investigators demonstrated equivalence in safety and
effectiveness between the HT Supreme and best-in-class DES.
"This trial was performed in the USA, Europe and Japan and the enrolled
patients reflect a broad spectrum of disease treated. The HT Supreme performed
very well and showed results non-inferior to the current market leading stent,"
said Prof. Andreas Baumbach from St. Bartholomew's Hospital, London, England,
and European Co-Principal Investigator. "I am now looking forward to see
whether the novel design of the stent platform and drug delivery system will
result in superior outcomes in future long-term follow-up out to five years."
The PIONEER III study enrolled 1,629 patients from centres in Belgium, Canada,
France, Germany, Japan, Netherlands, Spain, Switzerland, U.K., and the U.S.A.
This tri-continent trial had a primary composite endpoint of target lesion
failure (TLF) at one-year. The TLF outcomes showed that the HT Supreme met the
non-inferiority endpoint at 5.4% compared to 5.1% from the control arm
(p=0.002) of Xience and Promus devices (DP DES).
A grouped analysis of secondary endpoints showed a numerically better result
for HT Supreme in cardiac death or target-vessel myocardial infarction (TV MI)
with 3.5% in the HT Supreme arm compared to 4.6% in the control arm (p=0.27).
Lower late stent thrombosis data (0.1% compared to 0.4%, p=0.22) also suggested
exceptional safety for the HT Supreme.
"PIONEER III is the cornerstone of our extensive, international clinical trial
program and I am very grateful for the support we have had from investigators
around the world," said Dr. Jianhua Sun, PhD., chairman and chief executive
officer of SINOMED. "Now is a very exciting time for us as we are in the early
stage of product launch where we are putting our clinical learnings towards
real-life clinical experience."
A powered, landmark TLF analysis evaluating the healing superiority of HT
Supreme between 1 and 5 years is ongoing. Data from this trail will be
submitted to the U.S. Food and Drug Administration (FDA) for approval in the
U.S.A. and the and Pharmaceuticals and Medical Devices Agency (PMDA) for
approval in Japan.
The HT Supreme represents a novel class of stents that highlights the
importance of early, timely healing. Through patented designs and proprietary
processes, the HT Supreme is tailored to help patients accelerate their
wound-healing process and restore their naturally protective vessel function.
The HT Supreme was launched this summer in Europe and China.
More information on the PIONEER III study is available at
www.clinicaltrials.gov, identifier: NCT03168776.
About SINOMED
SINOMED is a global medical device company engaged in research, development,
production, and commercial distribution of interventional devices. We are
focused on developing breakthrough technologies to target unmet clinical needs
in the interventional treatment of coronary, neurovascular and structural heart
disease. Our mission is to expose more patients to the benefits of our medical
innovations, increasing patient longevity and quality of life. For more
information visit www.sinomed.com.
SINOMED B.V
Cindy Zheng
T: +31 10 307 6295
E: cindy.zheng@sinomed-eu.com
Logo - https://mma.prnewswire.com/media/1666903/SINOMED_Logo.jpg
Source: SINOMED
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。